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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not MDMAassisted psychotherapy is an effective treatment for posttraumatic stress disorder (PTSD).
Study Design: Systematic review of three published, randomized controlled trials (double-blind,
placebo-controlled) between 2008-2013.
Data Sources: All articles used were published in English, in peer-reviewed journals, and found
using PubMed/MEDLINE and Cochrane Review databases.
Outcomes Measured: The primary outcome measure in all three studies was the severity of
PTSD symptoms. The primary outcome measure was assessed using the Clinician-Administered
PTSD Scale (CAPS) and the Severity of Symptoms Scale for PTSD (SSSPTSD).
Results: All trials demonstrated a larger group mean reduction in CAPS/SSSPTSD scores for the
MDMA group compared to the placebo group. One study found these results to be statistically
significant (P = 0.015) and a considerable clinical response was seen with the MDMA-AP group
with a NNT of 2.
Conclusions: Based on the studies, all reported that the use of MDMA-AP reduced group mean
scores from baseline to a larger extent than placebo. Although the studies showed a similar
outcome, further studies with larger, heterogeneous sample sizes need to be performed to assess
the safety and efficacy of MDMA-AP as a treatment for PTSD.
Key Words: MDMA, PTSD
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INTRODUCTION
Posttraumatic stress disorder (PTSD) is a highly prevalent and costly mental health
disorder that often causes significant impairment in multiple areas of functioning.1 The lifetime
prevalence of PTSD in the United States is approximately 8%, with rates differing between
females and males at 10% and 4%, respectively.2 Comorbidities are common among PTSD
sufferers, with 66% of those diagnosed having two or more psychiatric and/or medical issues,
such as depressive disorders, anxiety disorders, and/or substance-related disorders.3 The exact
cost and number of healthcare visits due to PTSD have yet to be determined, though a study
performed by the Congressional Budget Office found the average costs for the first year of
treatment among veterans to be approximately $8,300 per patient.4 In addition, approximately
45-60% of mental health issues are treated in primary care, with primary care typically being the
location of the first presentation for those with disturbances due to psychiatric reasons.2
PTSD is a psychiatric illness that commonly manifests in individuals who have witnessed
or experienced a traumatic life event, such as death, disastrous injury, or sexual abuse. The
development of PTSD does not occur in all individuals who have experienced a traumatic event,
though some have certain risk factors and preexisting conditions that make them more
susceptible than others. These risk factors, such as being female and the presence of childhood
trauma, combined with biological theories suggesting hypothalamo-pituitary-adrenal axis
overactivity, autonomic nervous system overactivity, and alterations in norepinephrine levels and
receptors, contribute to the evolution of PTSD.1 Common symptoms that are characteristic of
PTSD include flashbacks, nightmares, distressing dreams or memories, sleep disturbances,
hypervigilance, exaggerated startle response, and avoidance of thoughts, objects, people, or
places that remind the patient of the traumatic event. According to the Diagnostic and Statistical
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Manual of Mental Disorders (DSM-5), a diagnosis of PTSD can be given to patients over 6 years
of age who meet the following criteria: (a) exposure to actual or threatened death, serious injury,
or sexual violence; (b) presence of at least one intrusion symptom; (c) persistent avoidance
symptoms; (d) negative alterations in cognitions and mood associated with the traumatic event;
(e) marked alterations in arousal and reactivity associated with the traumatic event; (f) duration
of the disturbance is more than one month; (g) the disturbance causes clinically significant
distress or impairment in social, occupational, or other important areas of functioning; and (h)
the disturbance is not attributable to the physiological effects of a substance or another medical
condition.1
Current treatment options for PTSD include pharmacotherapy and psychotherapy. Two
pharmacotherapeutic agents – sertraline (Zoloft) and paroxetine (Paxil) – have FDA approval for
the treatment of PTSD.5,6 Cognitive behavioral therapy (CBT) and prolonged exposure therapy
(PE) are well known psychotherapeutic options that, although effective, have substantial dropout
rates.7,8 Patients undergoing CBT or PE are asked to recollect their frightening memories many
times within a secure setting with the goal of inducing elimination of the undesirable trauma/fear
response. The psychotherapeutic treatment, however, is an arduous process that is
psychologically and emotionally taxing and commonly exacerbates symptoms before they
meliorate.8 Patients often feel overwhelmed during therapy and avoidance behavior – a hallmark
symptom of PTSD – often overpowers their ability to persevere through psychotherapy
sessions.9 Additionally, many PTSD patients have difficulty building interpersonal and trusting
bonds – an essential component to successful treatment. Seeing that 70-80% of those with PTSD
are unresponsive to pharmacotherapeutics and dropout rates in psychotherapeutic trials range
from 20-30%, it is evident that novel therapeutic options must emerge.7,8,9
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MDMA (Methylenedioxymethamphetamine)-assisted psychotherapy (MDMA-AP) is a
developing method that has shown promise in clinical trials for the treatment of PTSD. MDMAAP utilizes a psychoactive drug called MDMA as an adjunct to psychotherapy. The subjective
psychological effects of MDMA include diminished anxiety, reduced depression, increased
relaxation, euphoria, elevated feelings of trust, expanded insight, and mitigated fear response.1 It
is hypothesized that MDMA, when given in a safe context, produces unique psychological
effects that allow those with PTSD to engage in, optimize, and endure psychotherapy sessions.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not MDMA-AP is
an effective treatment for PTSD.
METHODS
The criteria used in the selection of the three randomized controlled trials (RCTs) for this
review were patients 18 years or older who met DSM-III-R, DSM-IV, or DSM-IV-R
requirements for PTSD. The intervention that was studied was MDMA-AP. MDMA-AP needed
to be compared to psychotherapy with concomitant administration of either active placebo or
inactive placebo. Two articles compared psychotherapy with concomitant MDMA administration
to the same psychotherapy accompanied by inactive placebo administration. One article
compared psychotherapy with concomitant full-dose (125 mg) MDMA administration to the
same psychotherapy accompanied by low-dose (25 mg) MDMA administration. The outcomes
measured were a reduction in the severity of symptoms associated with PTSD. Studies utilized in
this selective EBM review included three randomized, double, placebo controlled clinical trials.
Two databases were used (PubMed/MEDLINE and Cochrane Library) to find all three
articles on MDMA-AP. The search included the terms “MDMA” and “PTSD.” All articles were
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written in English and published in peer-reviewed journals between the years 2008 and 2013.
The articles were selected based on their relevance to the clinical question and for their focus on
patient-oriented outcomes (POEMs). Inclusion criteria comprised studies that were RCTs with
publication dates from 2004 to present. Exclusion criteria consisted of patients under the age of
18, as well as pregnant and/or lactating women. The statistics included were mean change from
baseline, p-values, and numbers needed to treat (NNT). Table 1 demonstrates the demographics
and characteristics of the studies chosen for this review.
Table 1. Demographics and characteristics of included studies
Study

Type

#pts

Bouso et al
(2008)7

Randomized,
double blind,
placebo
control

6

Mithoefer
et al
(2011)8

Randomized,
double blind,
placebo
control

23

Age
(yrs)
29 49

Inclusion Criteria

Exclusion Criteria

W/D

Interventions

-Women with
chronic, treatmentresistant PTSD
secondary to sexual
assault
- Score > 15 on
SSSPTSD

-Pregnant women
-Medication usage
in the month prior
to the start of the
study

0

21 70

Men and women
aged 21-70 years
who meet DSM-IVR criteria for the
diagnosis of crime
or war-related
chronic PTSD and
have treatmentresistant symptoms,
defined as a CAPS
score of greater than
or equal to 50
following at least 3
months of prior
SSRI or SNRI
treatment in addition
to at least 6 months
of psychotherapy.

-Freedom from any
major medical
conditions
-Borderline
Personality
Disorder or any
current Axis I
Disorder
(exceptions: anxiety
disorders, affective
disorders other than
bipolar disorder
type 1, substance
abuse or
dependence in
remission for
greater than or
equal to 60 days,
and eating disorder
without active
purging)

2

-MDMA 50-75
mg (n=4);
placebo (n=2)
-MDMA or
placebo given
during one 6hour
experimental
psychotherapy
session
-MDMA 125
mg (n=12);
placebo (n=8)
-MDMA or
placebo given
during two 8hour
experimental
psychotherapy
sessions
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Oehen et
al (2013)9

Randomized,
double blind,
active control

14

23 67

Men and women
who met the DSMIV-text revision
(TR) criteria for
PTSD with
treatment-resistant
symptoms, as
indicated by a
CAPS score of
greater than or equal
to 50 and having
previously
undergone at least 6
months of
psychotherapy and 3
months of treatment
with an SSRI.

-Significant medical
conditions, except
for hypothyroidism
under hormonal
replacement
-Psychiatric
conditions: hx of
psychotic illness,
bipolar disorder
type I, borderline
personality
disorder,
dissociative identity
disorder, and
substance abuse or
dependence within
60 days of
enrollment
-Use of MDMA on
more than five
occasions or less
than 6 months prior
to enrollment

2

-MDMA 25 mg
+ 12.5 mg 2.5
hours later
(n=4); MDMA
125 mg + 62.6
mg 2.5 hours
later (n=8)
-MDMA or
placebo given
during three 8hour
experimental
psychotherapy
sessions

OUTCOMES MEASURED
The severity of PTSD symptoms was the primary outcome measure in the selected
studies. In the Bouso et al study, outcome measures used were the Severity of Symptoms Scale
for Posttraumatic Stress Disorder (SSSPTSD) which assesses the main symptoms of PTSD.7 In
the Mithoefer et al study, outcome measures used include the Clinician-Administered PTSD
Scale (CAPS). The CAPS quantifies PTSD symptoms.8 In the Oehen et al study, outcome
measures used were a widely-used German version of the CAPS.
RESULTS
The Bouso et al study7 performed in 2008 was a double blind RCT consisting of 6
patients with treatment-resistant PTSD (failed at least 1 prior treatment for PTSD) and a baseline
SSSPTSD larger than 15. Of these patients, 3 received 50 mg MDMA, 1 received 75 mg
MDMA, and 2 received placebo. Each patient endured 7 psychotherapy sessions of 1 hour 30
minutes’ duration, with only 1 psychotherapy period coexisting with MDMA or placebo. This
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experimental psychotherapy session was the 4th session out of a total of 8 sessions and
commenced with either MDMA or placebo ingestion. The experimental session lasted a total of
6 hours. Baseline and post-treatment SSSPTSD scores were calculated and results were reported
as a group mean change from baseline. The results from this study showed larger improvements
in group mean score for the MDMA group compared to the placebo group, with a mean
SSSPTSD score reduction of 9 for the MDMA group vs 4.5 for the placebo group. These
changes correspond to a 24.1% average reduction for the MDMA group compared to 10.1%
reduction for the placebo group (Table 2). The difference between the mean change from
baseline was primarily powered by greater decreases in the reexperiencing and avoidance
subdivisions of the SSSPTSD.7 It should be noted that the patient receiving 75 mg of MDMA
plus psychotherapy achieved a 16 point SSSPTSD score reduction. The results of the 75 mg
MDMA group were not considered here because there was only 1 patient in this group. Due to
the small size of the study, a statistical analysis between groups was not performed.7
Table 2. Mean SSSPTSD scores by group over time (pre-to post treatment)
Group

Baseline

Post-treatment

MDMA 50 mg (n=3)
Placebo (n=2)

37.3
44.5

28.3
40

Mean Reduction
from Baseline
9
4.5

Average Reduction
(%)
24.1
10.1

The Mithoefer et al study8 conducted in 2011 was a double blind RCT consisting of 20
patients with treatment-resistant PTSD (as outlined in Table 1). The study initially enrolled 23
patients, but 1 dropped out due to a relapse of depression, another due to issues with travel
expenses, and a 3rd was removed after an assessment revealed he was not treatment-resistant. The
2 experimental psychotherapy sessions (sessions 1 and 5; 8 hours per session) in this study were
performed with patients either receiving 125 mg MDMA or inactive placebo. Additionally, all
patients underwent 11 nondrug psychotherapy sessions, with each session lasting for 90 minutes.
CAPS scores were recorded at baseline (T1), 4 days after each of the 2 experimental sessions
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(T2, T3), and 60 days after the final experimental session (T4). The results of this study showed
mean CAPS scored improved over time in both groups (group vs time interaction p < 0.0005).
The MDMA group, however, showed significantly greater improvement compared to the
placebo group (group vs time interaction, p = 0.015) with a 68% reduction vs 25.2% reduction at
2 months following the second experimental session, respectively (Table 3). A clinically
significant response was defined as a > 30% reduction from baseline in CAPS total severity
score.8 The results showed that 83.3% (10/12 patients) of the MDMA-AP group and 25% (2/8)
of the placebo plus psychotherapy group achieved a clinical response. Furthermore, 10 patients
of the MDMA group no longer fulfilled DSM-IV requirements for PTSD compared with 2
patients of the placebo group.8 The absolute benefit increase (ABI) was calculated to be 58.3%
and the relative benefit increase (RBI) was calculated to be 233%, with a corresponding NNT of
2 (Table 4).
Table 3. Mean CAPS scores by group over time 1 (T1) – time 4 (T4)
Group

Baseline
(T1)

T2

T3

T4

Average
Reduction
(%)

P-value

25.5

Mean
Reduction
from
Baseline
53.7

MDMA (n=12)

79.2

37.8

29.3

68

0.015

Placebo (n=8)

79.6

74.1

66.8

59.1

20.5

25.2

Table 4. Clinical response and treatment effects of MDMA-AP
Study
Mithoefer et al,
2011

EER
83.3%

CER
25%

ABI
58.3%

RBI
233%

NNT
2

The Oehen et al study9 conducted in 2013 was a double blind RCT consisting of 12
patients with treatment-resistant PTSD (as outlined in Table 1). The study initially enrolled 14
patients, but 2 patients withdrew because of adverse events after the first experimental session.
The three experimental psychotherapy sessions were 8 hours in duration and were performed
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with patients either receiving high-dose MDMA (125 mg + 62.5-mg supplementary dose) or
low-dose MDMA (25 mg + 12.5-mg supplementary dose; “active placebo”). The experimental
sessions were intermixed with 12 weekly nondrug psychotherapy sessions of shorter duration.
CAPS scores were calculated at baseline (T0) and 3 weeks after the second (T1) and third (T2)
experimental sessions. CAPS scores were analyzed using 2-way ANOVA.9 The results indicated
CAPS mean scores increased from T0-T2 for the active placebo group and decreased from T0T2 for the high-dose MDMA group. Although there was a trend toward larger effects from
higher-dose MDMA, these results were not statistically significant (p = 0.066, Table 5).
Table 5. Effects of high-dose MDMA-AP vs low-dose MDMA-AP on mean CAPS scores
Group

T0

T1

T2
50.8

Mean Change
from Baseline
- 15.6

Average
Change (%)
- 23.5

High-dose
MDMA (n=8)
Low-dose
MDMA (n=4)

66.4

63.0

63.4

60.0

66.5

+ 3.1

+ 4.9

P-value
0.066

After the clinical trial, an open-label phase was initiated which allowed the 4 patients who had
received low-dose MDMA to receive 6 sessions of high-dose MDMA-AP. At one year following
completion of the open-label phase, average CAPS scores decreased by 52% (35 points) in these
4 patients. At one year follow-up, 5 of 12 subjects no longer fulfilled diagnostic requirements for
PTSD, 4 had moderate PTSD, 2 subjects reduced their PTSD severity level to mild. Furthermore,
one patient on disability and three patients on limited employment were able to go back to work
as full-time employees by the one year follow-up.9
There were no significant drug-related adverse events in any of the studies. Mithoefer et
al. did note larger increases in blood pressure, heart rate, and body temperature in the MDMA
group, but these effects resolved and returned to baseline in both groups at the end of each
experimental session.8
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DISCUSSION
This systemic review evaluated the three randomized controlled trials evaluated the
effectiveness of MDMA-AP as a treatment for PTSD. The study by Bouso et al. demonstrated
encouraging indications of efficacy through reductions in SSSPTSD scores for both groups,
although there were larger reductions in the MDMA-AP group (24.1%) vs placebo group
(10.1%) that were principally fueled by larger decreases in reexperiencing and avoidance. This
study, however, has an array of limitations due to its small sample size and enrollment of only
female subjects. Additionally, the ethnicity of the subjects was not reported and a statistical
analysis was not completed. The Mithoefer et al. study generated clinically and statistically
significant improvements in PTSD symptomatology as calculated by CAPS scores and a p-value
equal to 0.015 and a NNT of 2. Furthermore, 83.3% of the MDMA-AP group subjects no longer
met diagnostic criteria for PTSD. The drawbacks to this study include a small sample size
composed solely of Caucasians, with nearly 85% of these being female. The Oehen et al. study
showed a reduction in CAPS scores over time, with a trend toward larger effects from higherdose MDMA, although these results were not statistically significant (p = 0.066). Weaknesses in
this study include a small sample size composed entirely of Europeans, with most participants
being female. An additional pitfall is that all three RCTs in this systemic review exclusively
enrolled and treated subjects with chronic, treatment-resistant PTSD.
From a clinical standpoint, safety, affordability, and access are strong considerations
when making treatment decisions. Unfortunately, MDMA-AP may miss the mark in all three
categories. Although the trials demonstrated no serious drug-related adverse events, MDMA
intoxication has been known to cause hyperthermia, hyponatremia, seizures, hepatotoxicity, and
life-threatening increases in heart rate and blood pressure.6 These serious events, although

Rudd, MDMA-AP for PTSD 10

uncommon, limit the patient population that could benefit from this type of therapy.
Affordability of MDMA may be another forceful disadvantage considering the 6-8-hour length
of the therapy sessions and extended monitoring of patients, which often includes overnight
observation.7,8,9 Finally, with no current FDA-approved indications and a schedule I drug status,
medical access to MDMA is nearly impossible.6,7
CONCLUSION
The studies reviewed demonstrate inconclusive evidence as to whether or not MDMAassisted psychotherapy (MDMA-AP) is an effective treatment for posttraumatic stress disorder
(PTSD). Although all studies demonstrated obvious improvements in CAPS scores for MDMA
versus placebo, only one study showed statistical significance. Future studies will need larger
sample sizes and a heterogeneous group of patients to apply clinically and statistically significant
findings to a more global population. Additionally, future studies need to focus on comparing the
effectiveness MDMA-AP to other treatment options, such as the combined gold-standard
psychotherapy with SSRI therapy. For many, the use of MDMA-AP greatly reduced debilitating
PTSD symptoms, removed a PTSD diagnosis, and/or allowed a return to employment as a fulltime employee. These quality of life improvements are patient-oriented outcomes that cannot be
overlooked or forgotten. PTSD is a costly condition with the potential for devastating outcomes,
and further MDMA-AP studies need to be performed to assess its safety and clarify its
effectiveness as a treatment option for this common psychiatric illness.
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